116 related articles for article (PubMed ID: 38103948)
21. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.
Aoyama T; Murakawa M; Katayama Y; Shiozawa M; Ueno M; Morimoto M; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Hepatogastroenterology; 2015; 62(138):472-7. PubMed ID: 25916085
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail.
Kitamura K; Esaki M; Sone M; Sugawara S; Hiraoka N; Nara S; Ban D; Takamoto T; Mizui T; Shimada K
Ann Surg Oncol; 2022 Oct; 29(11):7047-7058. PubMed ID: 35691957
[TBL] [Abstract][Full Text] [Related]
23. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail.
Hank T; Hinz U; Tarantino I; Kaiser J; Niesen W; Bergmann F; Hackert T; Büchler MW; Strobel O
Br J Surg; 2018 Aug; 105(9):1171-1181. PubMed ID: 29738626
[TBL] [Abstract][Full Text] [Related]
24. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma.
Kimura K; Amano R; Nakata B; Yamazoe S; Hirata K; Murata A; Miura K; Nishio K; Hirakawa T; Ohira M; Hirakawa K
World J Surg Oncol; 2014 Nov; 12():360. PubMed ID: 25429841
[TBL] [Abstract][Full Text] [Related]
25. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis.
Yamamoto T; Yagi S; Kinoshita H; Sakamoto Y; Okada K; Uryuhara K; Morimoto T; Kaihara S; Hosotani R
World J Gastroenterol; 2015 Jan; 21(1):262-8. PubMed ID: 25574100
[TBL] [Abstract][Full Text] [Related]
26. Pancreatectomy with Mesenteric and Portal Vein Resection for Borderline Resectable Pancreatic Cancer: Multicenter Study of 406 Patients.
Ramacciato G; Nigri G; Petrucciani N; Pinna AD; Ravaioli M; Jovine E; Minni F; Grazi GL; Chirletti P; Tisone G; Napoli N; Boggi U
Ann Surg Oncol; 2016 Jun; 23(6):2028-37. PubMed ID: 26893222
[TBL] [Abstract][Full Text] [Related]
27. Preoperative Volume-Based PET Parameter, MTV2.5, as a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Cancer.
Kang CM; Lee SH; Hwang HK; Yun M; Lee WJ
Medicine (Baltimore); 2016 Mar; 95(9):e2595. PubMed ID: 26945350
[TBL] [Abstract][Full Text] [Related]
28. Optimal lymph-node dissection for pancreatic tail cancer.
Seo S; Uemura K; Sumiyoshi T; Kondo N; Okada K; Otsuka H; Murakami Y; Takahashi S
Surg Today; 2022 Sep; 52(9):1307-1312. PubMed ID: 35182251
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
[No Abstract] [Full Text] [Related]
30. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
31. Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment.
You MS; Lee SH; Choi YH; Shin BS; Paik WH; Ryu JK; Kim YT; Jang DK; Lee JK; Kwon W; Jang JY; Kim SW
BMC Cancer; 2019 Oct; 19(1):952. PubMed ID: 31615457
[TBL] [Abstract][Full Text] [Related]
32. Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer.
Crippa S; Cirocchi R; Maisonneuve P; Partelli S; Pergolini I; Tamburrino D; Aleotti F; Reni M; Falconi M
Eur J Surg Oncol; 2018 Jan; 44(1):24-30. PubMed ID: 29183639
[TBL] [Abstract][Full Text] [Related]
33. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
34. Pancreatic body and tail cancer and favorable metastatic lymph node behavior on the left edge of the aorta.
Tanaka K; Nakamura T; Asano T; Nakanishi Y; Noji T; Tsuchikawa T; Okamura K; Shichinohe T; Hirano S
Pancreatology; 2020 Oct; 20(7):1451-1457. PubMed ID: 32868183
[TBL] [Abstract][Full Text] [Related]
35. A new preoperative prognostic scoring system to predict prognosis in patients with locally advanced pancreatic body cancer who undergo distal pancreatectomy with en bloc celiac axis resection: a retrospective cohort study.
Miura T; Hirano S; Nakamura T; Tanaka E; Shichinohe T; Tsuchikawa T; Kato K; Matsumoto J; Kondo S
Surgery; 2014 Mar; 155(3):457-67. PubMed ID: 24462074
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive comparison of clinicopathological characteristics, treatment, and prognosis of borderline resectable pancreatic cancer according to tumor location.
Takeda T; Sasaki T; Inoue Y; Mie T; Furukawa T; Kanata R; Kasuga A; Matsuyama M; Ozaka M; Takahashi Y; Saiura A; Sasahira N
Pancreatology; 2020 Sep; 20(6):1123-1130. PubMed ID: 32753119
[TBL] [Abstract][Full Text] [Related]
37. Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer.
Sunagawa Y; Yamada S; Sato Y; Morimoto D; Sonohara F; Takami H; Inokawa Y; Hayashi M; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
Ann Surg Oncol; 2020 Jun; 27(6):2081-2089. PubMed ID: 31673938
[TBL] [Abstract][Full Text] [Related]
38. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study.
Kurahara H; Shinchi H; Ohtsuka T; Miyasaka Y; Matsunaga T; Noshiro H; Adachi T; Eguchi S; Imamura N; Nanashima A; Sakamoto K; Nagano H; Ohta M; Inomata M; Chikamoto A; Baba H; Watanabe Y; Nishihara K; Yasunaga M; Okuda K; Natsugoe S; Nakamura M
Langenbecks Arch Surg; 2019 Mar; 404(2):167-174. PubMed ID: 30649607
[TBL] [Abstract][Full Text] [Related]
39. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society.
Tsuchida H; Fujii T; Mizuma M; Satoi S; Igarashi H; Eguchi H; Kuroki T; Shimizu Y; Tani M; Tanno S; Tsuji Y; Hirooka Y; Masamune A; Mizumoto K; Itoi T; Egawa S; Kodama Y; Hamada S; Unno M; Yamaue H; Okazaki K;
Surgery; 2019 Dec; 166(6):997-1003. PubMed ID: 31445763
[TBL] [Abstract][Full Text] [Related]
40. Preoperative predictors for early recurrence of resectable pancreatic cancer.
Nishio K; Kimura K; Amano R; Yamazoe S; Ohrira G; Nakata B; Hirakawa K; Ohira M
World J Surg Oncol; 2017 Jan; 15(1):16. PubMed ID: 28069033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
